» Articles » PMID: 28423570

Identification of Long Non-coding RNAs GAS5, Linc0597 and Lnc-DC in Plasma As Novel Biomarkers for Systemic Lupus Erythematosus

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Apr 21
PMID 28423570
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Despite increasing evidence that long non-coding RNAs (lncRNAs) widely take part in human diseases, the role of lncRNAs in systemic lupus erythematosus (SLE) is largely unknown. In this study, we performed a two-stage study to explore the plasma levels of five lncRNAs (GAS5, linc0949, linc0597, HOTAIRM1 and lnc-DC) and their potential as SLE biomarkers. Compared with healthy controls, plasma levels of GAS5 and lnc-DC were significantly decreased (P < 0.001 and P = 0.002, respectively) while linc0597 were overexpressed in SLE patients (P < 0.001). When SLE patients were divided into SLE without nephritis and lupus nephritis (LN), the levels of lnc-DC were significantly higher in LN compared with SLE without nephritis (P = 0.018), but no significant difference in levels of GAS5 and linc0597 were found between LN and SLE without nephritis; plasma linc0949 level showed no significant difference in all comparisons. Further evaluation on potential biomarkers showed that GAS5, linc0597 and lnc-DC may specifically identify patients with SLE, the combination of GAS5 and linc0597 provided better diagnostic accuracy; lnc-DC may discriminate LN from SLE without nephritis. In summary, GAS5, linc0597 and lnc-DC in plasma could be potential biomarkers for SLE.

Citing Articles

An updated review on abnormal epigenetic modifications in the pathogenesis of systemic lupus erythematosus.

Zhou X, Zhou S, Li Y Front Immunol. 2025; 15():1501783.

PMID: 39835138 PMC: 11743643. DOI: 10.3389/fimmu.2024.1501783.


The diagnostic and predictive potential of lncRNA CASC2 targeting miR-155 in systemic lupus erythematosus patients with nephritis complication.

Mohamed N, El-Fattah A, Shaker O, Sayed G Sci Rep. 2024; 14(1):30537.

PMID: 39690146 PMC: 11652638. DOI: 10.1038/s41598-024-81212-5.


Immunoregulatory role of AC007278.3 and HOTAIR long non-coding RNAs in lupus nephritis: potential biomarkers and therapeutic targets.

Rasuli E, Javidi-Aghdam K, Akbarzadeh-Khiavi M, Abdshah A, Gadakchi L, Jafarpour M Mol Biol Rep. 2024; 51(1):1075.

PMID: 39425850 DOI: 10.1007/s11033-024-10019-4.


Biological functions and affected signaling pathways by Long Non-Coding RNAs in the immune system.

Ghahramani Almanghadim H, Karimi B, Valizadeh S, Ghaedi K Noncoding RNA Res. 2024; 10:70-90.

PMID: 39315339 PMC: 11417496. DOI: 10.1016/j.ncrna.2024.09.001.


Exosomal Non-coding RNA Derived from Mesenchymal Stem Cells (MSCs) in Autoimmune Diseases Progression and Therapy; an Updated Review.

Farhan S, Jasim S, Bansal P, Kaur H, Abed Jawad M, Qasim M Cell Biochem Biophys. 2024; 82(4):3091-3108.

PMID: 39225902 DOI: 10.1007/s12013-024-01432-4.


References
1.
Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

2.
Wang H, Peng W, Ouyang X, Li W, Dai Y . Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 2012; 160(3):198-206. DOI: 10.1016/j.trsl.2012.04.002. View

3.
Carlsen A, Schetter A, Nielsen C, Lood C, Knudsen S, Voss A . Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 2013; 65(5):1324-34. PMC: 6662589. DOI: 10.1002/art.37890. View

4.
Zhao M, Liu S, Luo S, Wu H, Tang M, Cheng W . DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun. 2014; 54:127-36. DOI: 10.1016/j.jaut.2014.07.002. View

5.
Qu B, Cao J, Zhang F, Cui H, Teng J, Li J . Type I Interferon Inhibition of MicroRNA-146a Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015; 67(12):3209-18. DOI: 10.1002/art.39398. View